Ketan Desai
View Ketan Desai's Articles BY TICKER:
ABT,
ADLS.PK,
AGU,
ALXN,
AMGN,
ARNA,
ASTM,
ATHX,
AZN,
BHP,
BHRT.OB,
BIIB,
BMY,
CGNOF.PK,
CUR,
CYTX,
DBA,
DGX,
DNDN,
EBS,
EGPT,
ELN,
FAS,
FAZ,
FRX,
GAF,
GE,
GERN,
GILD,
GSK,
HCA,
HGSI,
ICN,
IFN,
IIF,
INP,
INR,
JNJ,
LH,
LJPC,
LLY,
MES,
MNKD,
MON,
MRK,
MYGN,
NVS,
OREX,
OSIR,
PFE,
PIP,
POT,
PPDI,
RDY,
REGN,
RHHBY.PK,
RIO,
RJA,
SIGA,
SNY,
STEM,
TBT,
THC,
TIP,
TNA,
TRGT,
TTM,
TZA,
UHS,
VALE,
VRTX,
VRUS,
VVUS,
WYE
- Results Of My Options Strategy For Vivus
- Another Option Strategy For Vivus
- Merck's Oral Immunotherapy For Allergic Rhino-Conjunctivitis
- The Battle For The Anti-Coagulation Market
- India's Iran Gambit: The Hunt For Oil
- Targacept Stumbles Again
- Depressing Results From Targacept's Phase III Study
- Investing In A Charlie Brown Market: Options In Leveraged ETFs
- One Way To Profit With Leveraged ETFs
- When to Buy Biotechnology Stocks?
- Earnings: What Happened to Dendreon?
- Accountable Care Organizations: The Effect on Medical Care and Healthcare-Related Stocks
- How Investors Should Play India's Troubling Demographics
- Who Will Win the Hepatitis C Market?
- Human Genome Sciences Options Prior to the FDA Decision
- Will Merck Succeed Where Pfizer Did Not?
- What Now for Egypt?
- Abbott the Only One Left in the Osteoarthritis Game
-
India's Contradictory Economics
on Mon, Nov 15, 2010 • 8 Comments
- 4 Lessons From a Review of Arena Articles
- The Economic and Political Implications of Afghan Gold
- Human Genome Sciences: Tests Raise Questions About New Lupus Drug
- Eli Lilly and GlaxoSmithKline: A Tale of Two Different Pharmas
- J&J Has Success with Psoriasis Treatment
- On Investment and Optimism
- Another Positive Indication for Amgen's Denosumab
- Myriad Genetics: I Told You So
- Limited Investment Opportunities in Indian Pharmaceutical Services
- Cangene: Canada's Answer to Bioterrorism
- Elan, Wyeth: Response to Skeptics on Alzheimer's Data
-
Bioterrorism: Anthrax and Biotech Companies
- Bioterrorism: Smallpox and Biotech Companies
